Diuretic resistance: reduced bioavailability and effect of oral frusemide.
作者信息
Odlind B O, Beermann B
出版信息
Br Med J. 1980 Jun 28;280(6231):1577. doi: 10.1136/bmj.280.6231.1577.
Abstract
摘要
相似文献
1
Diuretic resistance: reduced bioavailability and effect of oral frusemide.
Br Med J. 1980 Jun 28;280(6231):1577. doi: 10.1136/bmj.280.6231.1577.
2
Bioavailability of two preparations of frusemide.
N Z Med J. 1980 Mar 26;91(656):208-10.
3
Mannitol and frusemide in the treatment of diuretic resistant oedema in nephrotic syndrome.
Arch Dis Child. 1999 Feb;80(2):184-5. doi: 10.1136/adc.80.2.184.
4
Diuretic resistance?
Lancet. 1979 Feb 3;1(8110):253-4.
5
[Synergistic effect of furosemide and metolazone in edema cases difficult to handle].
Lakartidningen. 1987 Mar 11;84(11):846.
6
The effect of frusemide on 'resistant' oedema.
Singapore Med J. 1967 Dec;7(4):250-2.
7
Use of furosemide, a new oral diuretic, in the nephrotic syndrome.
Mich Med. 1966 Nov;65(11):949-52.
8
Discrimination between five oral frusemide preparations using renal chloride excretion and frusemide recovery.
N Z Med J. 1983 Nov 23;96(744):963-6.
9
Bioavailability of frusemide.
N Z Med J. 1980 May 28;91(660):403-4.
10
Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin?
BMJ. 1995 Jan 21;310(6973):162-3. doi: 10.1136/bmj.310.6973.162.
引用本文的文献
1
Diuretics in patients with chronic kidney disease.
Nat Rev Nephrol. 2025 Apr;21(4):264-278. doi: 10.1038/s41581-024-00918-x. Epub 2025 Jan 7.
2
Nephrotic Syndrome: Oedema Formation and Its Treatment With Diuretics.
Front Physiol. 2019 Jan 15;9:1868. doi: 10.3389/fphys.2018.01868. eCollection 2018.
3
Diuretic Resistance.
Am J Kidney Dis. 2017 Jan;69(1):136-142. doi: 10.1053/j.ajkd.2016.08.027. Epub 2016 Nov 1.
4
Pharmacokinetics of loop diuretics in congestive heart failure.
Br Heart J. 1994 Aug;72(2 Suppl):S40-3. doi: 10.1136/hrt.72.2_suppl.s40.
5
Pharmacokinetic changes in patients with oedema.
Clin Pharmacokinet. 1995 May;28(5):405-18. doi: 10.2165/00003088-199528050-00005.
6
The influence of ascites on the pharmacokinetics of piretanide in cirrhotic patients.
Eur J Clin Pharmacol. 1985;28(5):581-3. doi: 10.1007/BF00544070.
7
Bioavailability of bumetanide in grossly oedematous patients.
Clin Pharmacokinet. 1987 Jun;12(6):440-3. doi: 10.2165/00003088-198712060-00004.
8
Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).
Clin Pharmacokinet. 1990 Jun;18(6):460-71. doi: 10.2165/00003088-199018060-00003.
9
Absorption of high dose furosemide (frusemide) in congestive heart failure.
Clin Pharmacokinet. 1992 Apr;22(4):308-18. doi: 10.2165/00003088-199222040-00006.
本文引用的文献
1
Cyclical edema.
Am J Med. 1957 Oct;23(4):507-9. doi: 10.1016/0002-9343(57)90222-x.
2
Elimination of furosemide in healthy subjects and in those with renal failure.
Clin Pharmacol Ther. 1977 Jul;22(1):70-8. doi: 10.1002/cpt197722170.
3
Treatment of diuretic-resistant fluid retention with ultrafiltration.
Acta Med Scand. 1978;204(3):145-9. doi: 10.1111/j.0954-6820.1978.tb08416.x.
4
Pharmacokinetics/pharmacodynamics of furosemide in man: a review.
J Pharmacokinet Biopharm. 1979 Feb;7(1):1-27. doi: 10.1007/BF01059438.
Zotero 插件